Reproducibility of gene expression signature-based predictions in replicate experiments

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1721-1727

  Anderson, Keith ^a   Hess, Kenneth R ^a   Kapoor, Mini ^a   Tirrell, Stephen ^b   Courtemanche, Jean ^b   Wang, Bailiang ^a   Wu, Yun ^a   Gong, Yun ^a   Hortobagyi, Gabriel N ^a   Symmans, W Fraser ^a   Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

ACCURACY; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CORRELATION COEFFICIENT; DISCRIMINANT ANALYSIS; GENE EXPRESSION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY ANALYSIS;

BIOPSY, NEEDLE; BREAST; BREAST NEOPLASMS; CLINICAL LABORATORY TECHNIQUES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 33645696093     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1539     Document Type: Article

References (24)

1. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol 2002;20:1932-41.
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
3. Rouzier R, Perou CM, Symmans WF, et al. Different molecular subtypes of breast cancer respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
4. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
5. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93.
6. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
7. Symmans WF, Ayers M, Clark EA, et al. Total RNA yield and microarray gene expression profiles from fine needle aspiration and core needle biopsy samples of breast cancer. Cancer 2003;97:2960-71.
8. Stec J, Wang J, Coombes K, et al. Comparison of the predictive accuracy of DNA array based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn 2005;7:357-67.
9. Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS. Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 2002;18:405-12.
10. Irizarry RA, Warren D, Spencer F, et al. Multiple-laboratory comparison of microarray platforms. Nature Methods 2005;2:345-50.
11. Pusztai L, Symmans WF, Hortobagyi GN. Development of Pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 2005;12:73-85.
12. Baggerly KA. Detecting and correcting misalignment in Affymetrix data. 2002. The University of Texas M.D. Anderson Cancer Center, Department of BiostatisticsTechnical Report UTMDABTR-005-03. Available from: http://www.mdanderson.org/pdf/biostats_utmdabtr00503.pdf.
13. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2001;2:research0032.1-0032.11.
14. Lin L. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-68.
15. Hastie T, Tibshrani R, Friedman J. The elements of statistical learning. New York: Springer-Verlag; 2001.
16. Pusztai L, Hess KR. Clinical trial designs for microarray predictive marker discovery and assessment. Ann Oncol 2004;15:1731-7.
17. Mukherjee S, Tamayo P, Rogers S, et al. Estimating dataset size requirements for classifying DNA microarray data. J Comput Biol 2003;10:119-42.
18. Pusztai L, Hess KR, Gold DL, et al. Affymetrix gene chip profile predicts pathologic complete response to preoperative paclitaxel/FAC chemotherapy in breast cancer [abstract #306]. Breast Cancer Res Treat 2005;94:332.
19. Chu TM, Deng S, Wolfinger R, Paules RS, Hamadeh HK. Cross-site comparison of gene expression data reveals high similarity. Environ Health Perspect 2004;112:449-55.
20. Weis GK. Members of the Toxicogenomics Research Consortium: standardizing global gene expression analysis between laboratories and across platforms. Nature Methods 2005;5:351-6.
21. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-7.
22. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local central and reference laboratories in the NCCTG N9831 intergroup adjuvant trial. Proc Am Soc Clin Oncol 2004:18 [abstract 567].
23. Rhodes A, Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-30.
24. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-16.